Cargando…
CNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer
The use of immune checkpoint inhibitors that target programmed cell death‐1 (PD‐1) has been proposed for the treatment of advanced non‐small cell lung cancer (NSCLC). However, in clinical trials, cumulative response rates to anti‐PD‐1 treatment were approximately 20% in patients with NSCLC. CCR4‐NOT...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714061/ https://www.ncbi.nlm.nih.gov/pubmed/33034149 http://dx.doi.org/10.1002/2211-5463.12998 |